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Abstract
The visual-analogue scale (VAS), Likert item (rating scale), pills identification test (PIT), and medication possession ratio
(MPR) provide estimates of antiretroviral therapy (ART) adherence which correlate with HIV viral suppression. These simple
adherence measures are inexpensive and easy to administer; however, require validation and adjustment prior to
implementation. The objective of this study was to define the optimal adherence assessment measure in Namibia to identify
patients at risk for sub-optimal adherence and poor virologic response 6 months after ART initiation. We conducted a cross-
sectional survey in HIV-infected adults receiving ART for 6–12 months prior to the adherence assessment. Adherence
measures included 30-day VAS, 30-day Likert item, self-reported treatment interruptions, PIT, and MPR. Association of
adherence measures with 6-month HIV-1 RNA level was assessed using two thresholds (1000 copies/mL and 5000 copies/
mL). Adherence was assessed in 236 patients, mean age 37.3 years, 54% female. Mean adherence was 98.1% by 30-day VAS,
84.7% by 30-day Likert item, 97.0% by self-reported treatment interruptions, 90.6% by PIT, and 98.8% by MPR. Agreement
between adherence measures was poor using kappa statistic. 76% had HIV-1 RNA ,1000 copies/ml, and 88% had HIV-1
RNA ,5000 copies/ml. MPR (continuous) was associated with viral suppression ,5000 copies/ml (p = 0.036). MPR ,75%
was associated with virologic failure at $5000 copies/ml with OR 3.89 (1.24, 12.21), p = 0.013. Adherence was high with all
measures. Only MPR, was associated with short-term virologic response, suggesting its cross-culturally utility for early
identification of patients at high risk for virologic failure.
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Introduction
As of December 2011, over 8 million people infected with HIV
were receiving antiretroviral therapy (ART) in low- and middle-
income countries which represents a 26-fold increase since 2003
[1]. In June 2010, the United Nations General Assembly Special
Session (UNGASS) set a goal of placing 15 million individuals on
ART by 2015 [2]. Sustaining successful ART scale-up in resource-
limited settings depends largely upon the ability of ART programs
to deliver ART in a way that supports optimal patient adherence,
thereby maximizing durability of first- and second-line regimens.
Adherence to ART is a predictor of virologic suppression [3–8],
emergence of HIV drug resistance [9–10], disease progression
[11], and death [12–14].
Assessment of adherence by health care providers often results
in an overestimation of patients’ medication adherence [15].
Adherence as measured by a 30-day visual-analogue scale (VAS)
[16–17], Likert item (rating scale), pills identification test (PIT)
[18], and medication possession ratio (MPR) [6,19–21] have been
shown to be associated with viral suppression (adherence measures
defined in Methods Section). These simple adherence measures
are inexpensive and easy to administer. Reliable and simple
measures of adherence are essential components of ART
programs, especially in resource-limited settings. Although the
VAS, Likert item, PIT, and MPR have been demonstrated to be
valid measures of adherence, they require validation and
adjustment prior to implementation to account for local cultural
and linguistic factors.
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Namibia is a resource-limited country in sub-Saharan Africa
that has been severely affected by the HIV epidemic. In Namibia,
there are approximately 200,000 people living with HIV in a
population of 2.1 million [22–23]. Among 15–49 year olds,
approximately 18.8% are infected with HIV-1 [22]. The epidemic
is predominantly spread via heterosexual contact, and prevalence
estimates vary by region with up to 36% infected with HIV-1 in
the most heavily-affected areas in the north [22]. ART has been
available in Namibia’s private sector since 1998 and in the public
sector since 2003. In the public sector, ART is provided free of
charge following a population-based model of care [24]. At 90%,
Namibia has one of the highest ART coverage rates in Sub-
Saharan Africa with 88,717 eligible patients on ART as of
December 2010 [25]. At present, ART is available at all 40 public
hospitals and at an additional 111 satellite/outreach service points,
as well as 30 Integrated Management of Adolescent and Adult
Illness (IMAI) modules sites [24].
It is unclear which adherence measure would be most
appropriate for use in Namibia’s ART program. Therefore,
identifying the best tool to estimate patient adherence for Namibia
would be valuable for quality-improvement of the ART program
to minimize preventable HIV drug resistance and optimize patient
care. The objective of this study was to define the optimal cross-
cultural tool to provide ART care providers in Namibia with
information to identify patients at risk for sub-optimal adherence
and poor short-term virologic response.
Methods
We conducted a cross-sectional survey in 236 HIV-infected
adults in Namibia who had initiated ART 6–12 months prior to
the adherence assessment. Adherence measures included a 30-day
VAS, 30-day Likert item, self-reported treatment interruptions,
and PIT. Pharmacy dispensing records were used to calculate
MPR. A viral load was conducted 6 months after ART initiation
on all ART patients and used to assess association with adherence
measures. Viral load testing was conducted by the Namibian
Institute of Pathology utilizing COBAS AmpliPrep/COBAS
TaqMan HIV-1 Test (Hoffman-La Roche). The survey was
performed between September 2010 and April 2011.
Ethics Statement
Ethical approval was obtained from the institutional review
board at Tufts University School of Medicine in Boston, USA and
the Republic of Namibia Ministry of Health and Social Services
Ethics and Research Committee in Windhoek, Namibia. Written
informed consent was obtained from all participants.
Study Population
The study population consisted of patients diagnosed with HIV-
1 who were being prescribed adult ART and being managed at a
public ART delivery site in Windhoek, Namibia. Windhoek, the
largest urban setting in the country, has an estimated population of
342,000 (2009) [23].
Patients were recruited from the three major public ART
delivery sites in Windhoek: Katutura State Hospital, Katutura
Health Centre, and Windhoek Central Hospital. Patients were
eligible to be included in the survey if they were HIV positive,
started an adult ART regimen for the first time 6–12 months prior
to the date of the adherence assessment, were receiving an adult
ART regimen at the time of the adherence assessment, and had a
routine 6-month viral load available for analysis.
Study Adherence Measures
Adherence was measured at the routine ART clinic visit with
five different adherence measures: 1) VAS, 2) 5-choice Likert item,
3) self-reported treatment interruptions, 4) PIT, and 5) MPR. The
VAS asked the patient to mark an ‘‘X’’ on a continuous scale
describing his/her level of adherence to all their antiretroviral
(ARV) medications prescribed over the previous 30 days on a scale
of 0% to 100%. The position indicated by the patient was
converted to a percentage. The 5-choice Likert item asked the
patient to choose the word that most accurately described how
well they took their ARV medication during the past 30 days:
‘‘excellent’’, ‘‘very good’’, ‘‘good’’, ‘‘fair’’, and ‘‘poor’’. Self-
reported treatment interruptions were assessed by asking, ‘‘How
many times did you ever interrupt your ART for 2 days or more.’’
All self-reported adherence questions were preceded by a
statement asking for truthful answers, as they would be kept
strictly confidential and would in no way affect their future health
care. The PIT measured whether a patient was able to identify all
the medication that he/she was taking and state the number of
pills that should be taken and the time. The PIT used in this study
was adapted from the original PIT developed by Parienti et al
[18]. All routine ARV pills available in Namibia were included,
along with 1–2 ‘‘twin’’ pills, pills which differed only by one
characteristic (color, size, shape). The PIT score was calculated as
the sum of misidentifications weighted according to the degree of
resemblance of the pills (0.5 for the twin, 1 for other or omission).
Mistakes on how many pills per day resulted in +1. The patient’s
knowledge of ARV treatment was considered satisfactory if the
PIT score was lower than 1. The scoring system followed
previously published norms [18]. MPR measures the amount of
time an individual is in possession of their ARV pills as a
proportion of the time between 2 ARV pick-ups [26]. Data for
MPR were abstracted from the Electronic Dispensing Tool (EDT),
a standardized pharmacy record system used to dispense ART at
all public ART sites in Namibia, collecting data including date of
ART pick-up, ART regimen, and number of pills dispensed. MPR
was calculated for the entire time the patient was on ART until the
viral load with the formula: number of days ARV dispensed/
number of days between first and last ARV pick-up.
The standardized questionnaire was administered via face-to-
face interviews by a trained interviewer. The questionnaire was
translated into Oshiwambo and Afrikaans and back-translated and
pre-tested to ensure accuracy. The questionnaire was administered
in English, Oshiwambo or Afrikaans depending on the partici-
pant’s preference. English is the official language in Namibia; and
Oshiwambo and Afrikaans are spoken in 37% and 24% of
households respectively [27].
Statistical Analysis
Univariate statistics were obtained for each variable included in
this analysis. Frequencies and distributions were carefully exam-
ined for unusual values. For the outcome, we chose to look at viral
load level at two thresholds, ,1000 copies/mL and ,5000
copies/mL. These two thresholds were chosen to reflect the World
Health Organization (WHO) criteria for prevention of HIV drug
resistance (1000 copies/mL) [28] and treatment failure (5000
copies/mL) [29]. MPR was analyzed as a continuous variable and
then dichotomized at a threshold of 75%. The Likert item was
dichotomized at two different thresholds for adherence (Likert
A=Excellent, very good vs. good, fair, poor; Likert B=Excellent
vs. very good, good, fair, poor). VAS was analyzed as a continuous
variable and then dichotomized with adherent being defined as
.95%. A satisfactory PIT score was ,1. Self-reported 48-hour
Antiretroviral Adherence Measures Namibia
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treatment interruptions were dichotomized at $1 treatment
interruption over the entire period on ART.
Separate chi square analyses were conducted for each
adherence measure to determine if associations existed between
adherence and each viral load outcome. Bivariate associations
were examined between other relevant demographic and poten-
tially confounding variables and viral load using chi square tests
for categorical variables and Wilcoxon Rank Sum tests for ordinal
and continuous measures.
To assess bivariate associations between outcome variables and
each of the adherence measures and demographic variables of
interest, three statistical tests were used: Spearman rank correla-
tion was used to measure the association between two continuous
variables; Wilcoxon Rank Sum tests for the association between
binary and continuous variables; and Kruskal-Wallis tests for the
association between categorical and continuous variables.
The degree that adherence measures agreed with each other
was assessed. Agreement among the dichotomized measures of
adherence (VAS, Likert, PIT score and MPR, and self-reported
treatment interruption) was assessed using Cohen’s kappa statistic.
For all statistical analyses, an alpha of 0.05 was used to evaluate
statistically significant differences or associations. All analyses were
performed using PASW version 18 (IBM; Armonk, New York).
Results
Adherence to ART was assessed in 236 patients (Table 1), mean
age 37.3 years. Patients were 54% female (53.6% of patients on
ART in Windhoek are female) [unpublished data] and 86% single.
Mean time on ART was 263 days. At time of ART initiation, 26%
had WHO clinical stage 3 or 4; 9% had WHO clinical stage 3 or 4
at the time of the adherence assessment. Median CD4 cell count at
ART initiation was 186 cells/mL. The mean weight at ART
initiation was 58.5 kg and 61.0 kg at the time of the adherence
assessment. ART starting regimens are listed in Table 1. The
majority of patients (93%) reported no previous ART experience
and a treatment supporter (78%). Median monthly income was
1000 Namibian Dollars (US$ 124) (mean monthly income for
Namibia US$ 444) [30], and median distance from the ART clinic
was 4 km. Forty percent had less than secondary school education
and 59% had secondary school education.
Median and mean adherence was 100% and 98.1% respectively
by 30-day VAS. Ninety-six percent of respondents had a VAS
percent of .95%. By the 30-day Likert item 85% reported
‘‘excellent’’ or ‘‘very good’’ adherence and 48% of respondents
reported ‘‘excellent’’ adherence. Ninety-one percent of respon-
dents had a satisfactory PIT score. Median and mean adherence
by MPR was 100.0% and 98.8%. Ninety-three percent had$75%
MPR. Only 3% of respondents reported having one or more
treatment interruption of $48 hours. (Table 2).
Agreement between adherence measures was poor with low
Kappa statistic values. The VAS had higher agreement with self-
reported treatment interruptions (Kappa= 0.27; p,0.001 for $1
treatment interruptions) than other clinic-based measures. The
second highest agreement was VAS with 30-day Likert (Kap-
pa= 0.21; p,0.001 for Likert item excellent and very good vs.
good, fair and poor).
HIV-1 RNA was determined 6 months after ART initiation;
179/236 (76%) had HIV-1 RNA,1000 copies/mL, and 208/236
(88%) had HIV-1 RNA ,5000 copies/mL. MPR (continuous
variable) was significantly associated with viral suppression at
,5000 copies/mL (p= 0.036). Having MPR ,75% was signifi-
cantly associated with virologic failure at $5000 copies/mL with
OR 3.89 (1.24, 12.21), p = 0.013. MPR ,75% had borderline
significant association virologic failure at $1000 copies/mL with
OR 2.64 (0.94, 7.46), p = 0.058. No other adherence measure had
a significant association with viral load at $5000 copies/mL or
$1000 copies/mL.
Discussion
This study is the first reported ART adherence assessment
among HIV-infected patients in Namibia. The level of adherence
observed in the three public ART delivery sites in Windhoek,
Namibia was high as estimated by all five adherence measures.
This finding is consistent with previously published levels of
reported adherence in other African settings [16,31–33].
We used five different measures of adherence in this study to
assess for a cross-cultural and simple measure of adherence
associated with short-term virologic response. Viral load 6 months
after ART initiation was used as a marker for short-term virologic
response and was tested for associations with the different
adherence measures. As shown previously in other settings
[6,13,21,26], in Namibia we confirm that MPR was associated
with short-term virologic response. The threshold of ,75% MPR
was significantly associated with virologic failure $5000 copies/
mL at 6 months. This finding suggests that MPR may be a useful
tool to help identify patients at risk for early virologic failure in
Namibia and similar settings. Unlike patient self-reported adher-
ence measures, which are prone to recall or social desirability bias,
MPR is an objective measure because it does not rely on asking the
patient, but instead uses routine data from pharmacy visits.
Additionally, the MPR captures treatment interruptions because it
takes into account time periods without medication coverage.
Therefore, MPR may be an important tool in resource-limited
settings where many patients may experience treatment interrup-
tion due to lack of access to medications.
No other measure of adherence in this study was found to be
significantly associated with short-term virologic response. In
addition, agreement between adherence measures was poor.
These results could be explained by a variety of cultural-linguistic
factors and/or limitations with the tools themselves such as recall
and social desirability bias. In addition, some tools may be limited
in their adherence assessment depending on the reasons for poor
adherence and pattern of missed doses as detailed below.
The level of adherence by 30-day Likert in our study was high,
but was not associated with virologic suppression. Although, the
30-day Likert item has been validated in other settings, the
overestimation of adherence by these types of self-reported
adherence tools has been reported [34]. The discrepancy between
relatively high self-reported levels of adherence and low levels of
virologic suppression at 6 months suggests that there may have
been social pressure to report optimal adherence in this
population. It is worth mentioning that the Likert item only
assessed perceived adherence and not actual adherence by asking,
‘‘How well do you think you took your ARVs in the past 30 days?’’
Therefore, a respondent experiencing treatment interruptions due
to lack of access to their ART clinic may still report excellent
adherence by Likert because he/she did not choose to be non-
adherent. The same could be said of VAS. In our study, VAS
seemed to have performed even worse than the 30-day Likert item.
The overwhelming number of VAS responses was 100%
adherence (226 of 236; 95.8%). Additionally, seven of the ten
not responding 100% adherence were 50%. We hypothesize that
in this setting the concept of percentages used in the VAS may not
be understood as well as discrete categories used in the Likert item.
Self-reported treatment interruptions was also not associated with
virologic failure. An overwhelming proportion of respondents
Antiretroviral Adherence Measures Namibia
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Table 1. Characteristics of participants: 236 recent ART starters by viral load cutoff.
Characteristic Overall Viral load cutoff =1000 c/mL
(a) Viral load cutoff =5000 copies c/mL(a)
$1000 ,1000 P-value $5000 ,5000 P-value
(N=236) (n =57) (n =179) (n=28) (n =208)
Mean (SD),
Median (Q1,
Q3), or N (%)
Mean (SD),
Median (Q1,
Q3), or N (%)
Mean (SD),
Median (Q1,
Q3), or N (%)
Mean (SD),
Median (Q1,
Q3), or N (%)
Mean (SD),
Median (Q1,
Q3), or N (%)
Age 37.3 (8.5) 38.0 (8.4) 37.1 (8.6) 0.480 38.1 (8.5) 37.2 (8.5) 0.614
Sex
Male 108 (45.8) 27 (47.4) 81 (45.3) 0.780 10 (35.7) 98 (47.1) 0.256
Female 128 (54.2) 30 (52.6) 98 (54.7) 18 (64.3) 110 (52.9)
Marital status
Single 202 (85.6) 50 (87.7) 152 (84.9) 0.681 24 (85.7) 178 (85.6) 0.869
Married 32 (13.6) 7 (12.3) 25 (14.0) 4 (14.3) 28 (13.5)
Widowed 2 (0.8) 0 (0) 2 (1.1) 0 (0) 2 (1.0)
Education
None 31 (13.1) 9 (15.8) 22 (12.3) 0.225 2 (7.1) 29 (13.9) 0.507
Primary 63 (26.7) 18 (31.6) 45 (25.1) 11 (39.3) 52 (25.0)
Secondary 139 (58.9) 29 (50.9) 110 (61.5) 15 (53.6) 124 (59.6)
Diploma 2 (0.8) 0 (0) 2 (1.1) 0 (0) 2 (1.0)
Bachelor’s degree 1 (0.4) 1 (1.8) 0 (0) 0 (0) 1 (0.5)
Monthly income (Namibian $) 1000 (350, 1800) 1000 (350, 1900) 1000 (325, 1800) 0.867 800 (219, 1975) 1000 (350, 1788) 0.641
CD4 at start (cells/mL) 186 (124, 227) 163 (89, 209) 195 (137, 232) 0.016 158 (87, 236) 189 (134, 226) 0.294
Starting ART regimen(b)(c)
AZT/3TC/EFV 21 (8.9) 4 (7.0) 17 (9.5) 0.498 3 (10.7) 18 (8.7) 0.832
AZT/3TC/NVP 130 (55.1) 34 (59.6) 96 (53.6) 14 (50.0) 116 (55.8)
D4T/3TC/NVP 15 (6.4) 4 (7.0) 11 (6.1) 3 (10.7) 12 (5.8)
TDF/3TC/EFV 33 (14.0) 7 (12.3) 26 (14.5) 5 (17.9) 28 (13.5)
TDF/3TC/NVP 36 (15.3) 7 (12.3) 29 (16.2) 3 (10.7) 33 (15.9)
D4T/3TC/LVP/r 1 (0.4) 1 (1.8) 0 (0) 0 (0) 1 (0.5)
Days on ART 263.1 (57.0) 255.7 (56.0) 265.4 (57.4) 0.263 250.0 (54.2) 264.8 (57.3) 0.196
Prior ART exposure
Never on ART 219 (92.8) 53 (94.6) 166 (93.3) 0.830 24 (88.9) 195 (94.2) 0.462
Transfer in on ART 14 (5.9) 3 (5.4) 11 (6.2) 3 (11.1) 11 (5.3)
PMTCT 1 (0.4) 0 (0) 1 (0.6) 0 (0) 1 (0.5)
WHO clinical stage at start(d)
1 119 (50.4) 27 (49.1) 92 (53.2) 0.860 14 (51.9) 105 (52.2) 0.869
2 48 (20.3) 15 (27.3) 33 (19.1) 6 (22.2) 42 (20.9)
3 50 (21.2) 10 (18.2) 40 (23.1) 4 (14.8) 46 (22.9)
4 11 (4.7) 3 (5.5) 8 (4.6) 3 (11.1) 8 (4.0)
WHO clinical stage at end
1 191 (83.0 38 (67.9) 153 (87.9) ,0.001 16 (59.3) 175 (86.2) 0.001
2 19 (8.3) 7 (12.5) 12 (6.9) 6 (22.2) 13 (6.4)
3 15 (6.5) 10 (17.9) 5 (2.9) 5 (18.5) 10 (4.9)
4 5 (2.2) 1 (1.8) 4 (2.3) 0 (0) 5 (2.5)
Weight at start (kg) 58.5 (10.4) 58.6 (11.1) 58.5 (10.2) 0.933 59.0 (12.4) 58.4 (10.2) 0.787
Weight at end (kg) 61.0 (10.9) 61.0 (11.0) 61.0 (11.0) 0.973 61.9 (13.4) 60.9 (10.6) 0.672
Use of cotrimoxazole
Never 7 (3.0) 1 (1.8) 6 (3.4) 0.594 0 (0) 7 (3.4) 0.540
Current 223 (94.5) 55 (98.2) 168 (95.5) 27 (100) 196 (95.6)
Stopped 2 (0.8) 0 (0) 2 (1.1) 0 (0) 2 (1.0)
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reported never having a 48-hour treatment interruption (97%).
The literature has demonstrated that $48 hours of unplanned
treatment interruptions are associated with the development of
HIV drug resistance and increased risk of treatment failure [35–
36]. Although information about treatment interruptions is vital to
predicting treatment failure, self-reported treatment interruptions
Table 1. Cont.
Characteristic Overall Viral load cutoff =1000 c/mL
(a) Viral load cutoff =5000 copies c/mL(a)
$1000 ,1000 P-value $5000 ,5000 P-value
(N=236) (n =57) (n =179) (n=28) (n =208)
Mean (SD),
Median (Q1,
Q3), or N (%)
Mean (SD),
Median (Q1,
Q3), or N (%)
Mean (SD),
Median (Q1,
Q3), or N (%)
Mean (SD),
Median (Q1,
Q3), or N (%)
Mean (SD),
Median (Q1,
Q3), or N (%)
Use of treatment supporter
Yes 184 (78.0) 44 (77.2) 140 (78.2) 0.872 20 (71.4) 164 (78.8) 0.374
No 52 (22.0) 13 (22.8) 39 (21.8) 8 (28.6) 44 (21.2)
Distance travel to clinic (km) 4.0 (2.0, 6.0) 5.0 (3.0, 6.0) 3.0 (2.0, 6.0) 0.313 5.0 (3.0, 6.0) 3.0 (2.0, 6.0) 0.340
(a)c/mL = copies per milliliter.
(b)ART = antiretroviral therapy.
(c)NVP = nevirapine; EFV = efavirenz; TDF = tenofovir; 3TC = lamivudine; AZT = zidovudine; D4T = stavudine; LVP/r = lopinavir/ritonavir.
(d)WHO=World Health Organization.
doi:10.1371/journal.pone.0056307.t001
Table 2. Adherence measures by viral load cutoff.
Adherence
Measure Overall
Viral load
cutoff = 1000 c/mL(a) Virologic Failure
Viral load
cutoff = 5000 c/mL(a)
Virologic
Failure
(N=236)
$1000
(n =57)
,1000
(n =179) P-value
Odds Ratio
(95% CI)
$5000
(n =28)
,5000
(n =208) P-value
Odds Ratio
(95% CI)
N (%) N (%) N (%) N (%) N (%)
MPR(b) ($75%)
Adherent 220 (93.2) 50 (87.7) 170 (95.0) 23 (82.1) 197 (94.7)
Non-adherent 16 (6.8) 7 (12.3) 9 (5.0) 0.058 2.64 (0.94, 7.46) 5 (17.9) 11 (5.3) 0.013 3.89 (1.24, 12.21)
Likert A(c)
Adherent 200 (84.7) 50 (87.7) 150 (83.8) 23 (82.1) 177 (85.1)
Non-adherent 36 (15.3) 7 (12.3) 29 (16.2) 0.473 0.72 (0.30, 1.76) 5 (17.9) 31 (14.9) 0.683 1.24 (0.44, 3.52)
Likert B(d)
Adherent 113 (47.9) 27 (47.4) 86 (48.0) 15 (53.6) 98 (47.1)
Non-adherent 123 (52.1) 30 (52.6) 93 (52.0) 0.929 1.03 (0.57, 1.87) 13 (46.4) 110 (52.9) 0.521 0.77 (0.35, 1.70)
VAS(e) (.95%)
Adherent 226 (95.8) 55 (96.5) 171 (95.5) 27 (96.4) 199 (95.7)
Non-adherent 10 (4.2) 2 (3.5) 8 (4.5) 0.754 0.78 (0.16, 3.77) 1 (3.6) 9 (4.3) 0.852 0.82 (0.10, 6.72)
PIT(f) score (,1)
Adherent 213 (90.6) 53 (93.0) 160 (89.9) 25 (89.3) 188 (90.8)
Non-adherent 22 (9.4) 18 (10.1) 4 (7.0) 0.485 0.67 (0.22, 2.07) 19 (9.2) 3 (10.7) 0.793 1.19 (0.33, 4.29)
Treatment Int(g)
Adherent 229 (97.0) 54 (94.7) 175 (97.8) 27 (96.4) 202 (97.1)
Non-adherent 7(3.0) 3 (5.3) 4 (2.2) 0.364(h) 2.43 (0.53, 11.20) 1 (3.6) 6 (2.9) 0.592(h) 1.25 (0.14, 10.75)
(a)c/mL = copies per milliliter.
(b)MPR =Medication possession ratio.
(c)Likert A = Excellent, very good vs good, fair, poor.
(d)Likert B = Excellent vs very good, good, fair, poor.
(e)VAS =Visual analogue scale.
(f)PIT = Pills identification test.
(g)Treat Int = Self-reported treatment interruptions $1.
(h)Fisher’s exact test.
doi:10.1371/journal.pone.0056307.t002
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may not be a valid method of obtaining this information. Self-
reported treatment interruptions may have been affected by recall
bias or social desirability bias. Also, treatment interruptions may
have been interpreted to be self-imposed interruptions of therapy
instead of interruptions due to lack of access to medications.
To our knowledge, this is the first study assessing PIT in Sub-
Saharan Africa. As the PIT requires minimal use of words because
it involves primarily identification of the pills or pictures of pills
[18], it has been suggested that PIT may be useful for assessing
adherence in resource-limited settings and may be a better cross-
cultural tool. However, we found no association of the PIT with
viral suppression. Importantly, a large proportion of patients
correctly identified their ARV medication (91%). In the original
context in France the PIT was developed and validated at a time
when ART regimens were more complex. In settings where ART
regimens are simplified and fewer regimens are in use such as in
resource-limited settings, the PIT may not discriminate between
high and low adherence. Also in the original context where the
PIT was developed and assessed [18], non-adherence was mainly
related to ‘‘perceived side effects’’, carelessness and forgetting to
take medications (individual patient adherence) and not associated
with structural barriers (free drugs, home-hospital travel reim-
bursements, drug continuity). In contrast, treatment interruptions
due to structural barriers have been demonstrated to be a critical
reason for missed doses in resource-limited setting [36]. Therefore,
we hypothesize that many subjects in our cohort recognized and
identified their pills perfectly, but simply experienced treatment
interruptions due to structural barriers, and thus developed HIV
drug resistance and/or treatment failure. In this case where
structural barriers may be more important than individual patient
adherence, MPR would best capture this partial exposure to ARV
drugs.
This study has several limitations. First, we conducted the
adherence assessment in Windhoek, which is not representative of
the country. However, because Windhoek has a mixture of the
different socio-economic and ethnic populations present in
Namibia, we would expect similar understanding and usefulness
of these adherence tools. Results though may not be as
generalizable to rural populations. Second, adherence assessments
were conducted a mean two months after the 6-month viral load.
This lag period leaves open the possibility that the lack of
association between self-reported adherence and viral load was
due to a change in viral load [37] or patient adherence during that
time. Third, the 6-month viral load may not be the best surrogate
for long-term virologic response. However, recent data indicate
that the 6-month viral load may predict subsequent survival,
retention in care and switch to second-line therapy [38].
Importantly, identification of an adherence measure that is
associated with 6-month viral load may be useful for early
identification of those who are at risk of suboptimal adherence.
These at-risk patients can then receive targeted interventions to
optimize patient care and minimize the emergence of drug
resistance.
In conclusion, this study provides the first data from Namibia
describing levels of ARV adherence comparing multiple adher-
ence measures. The levels of adherence were high with all
adherence measures, but self-reported adherence measures were
not associated with virologic failure. Depending on the reasons
and patterns of missed doses in particular populations, some tools
may be more helpful than others. In resource-limited settings, self-
reported adherence measures may be less useful tools because non-
adherence and thus virologic failure may be due more to lack of
access to medications rather than individual reasons for poor
adherence. MPR was found to be associated with short-term
virologic response, which suggests its utility in early identification
of patients at high risk for virologic failure in resource-limited
settings. Future research should focus on identifying optimal
adherence measure tools for resource-limited settings where lack of
access to medications may be the primary driver for treatment
failure.
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